San Francisco Biotech Networks

SFBN Feed: United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026 https://lnkd.in/gVDnhmeV LOS ANGELES, May 31, 2026 /PRNewswire/ — United Imaging, a global innovator in AI-powered advanced medical imaging technologies and intelligent healthcare solutions, is presenting its latest molecular imaging advancements at the Society of Nuclear Medicine and Molecular Imaging (SNMMI)… Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

SFBN Feed: ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’ https://lnkd.in/gWmNCgnF The German biotech shared updated data from a phase 1 study of the antibody-drug conjugate TUB-040, the star behind Gilead’s decision to buy the company for $3.15 billion upfront earlier this year. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

SFBN Feed: Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026 https://lnkd.in/gW2vij8n ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held fr Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

SFBN Feed: ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer https://lnkd.in/gs_KVPc6 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $VCYT #ASCO26–ENZAMET Trial Shows Veracyte’s Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

SFBN Feed: Brayton Purcell LLP Highlights Investigative Report on California’s Silicosis Crisis Linked to Artificial Stone https://lnkd.in/gxmnhP9A NOVATO, Calif., May 29, 2026 /PRNewswire/ — Brayton Purcell LLP is calling attention to a newly published investigative report detailing California regulators’ response to a growing silicosis crisis among countertop fabrication workers exposed to artificial stone. The article,… Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

SFBN Feed: Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy https://lnkd.in/gQTD7P8i SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it will host a conference call and webcast on Monday, June 1, 2026, at 8:00 a.m. ET to discuss results from the ongoing Phase 1 healthy volunteer study of JADE101. The data are expected to define the dosing strategy and further characterize JADE101’s clinical profile as a potentially differentiated, disease-modifying anti–A Proliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A nephropathy (IgAN). Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

SFBN Feed: BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026 https://lnkd.in/g67GXMrb SAN CARLOS, Calif.–(BUSINESS WIRE)—- $ONC #BeOne–BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further suppo Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

SFBN Feed: Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist field https://lnkd.in/gBfhJR25 Gilead has abandoned work on the lead rheumatoid arthritis drug from its $405 million buyout of MiroBio in the latest blow to the BTLA agonist field. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

SFBN Feed: Lung cancer took tech exec Susan Wojcicki’s life. Now her family is doubling down on early diagnosis, treatment https://lnkd.in/gMHSbXTJ Non-small cell lung cancer is typically slower growing but makes up 85% of lung cancer cases. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

SFBN Feed: BizSpotlight: NovoMed https://lnkd.in/gx_Kup6C NovoMed Medical offers Sacramento’s premier concie Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News